My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Beam Therapeutics Inc. - Common Stock
(NQ:
BEAM
)
25.42
+0.03 (+0.12%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Beam Therapeutics Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
November 26, 2024
Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies.
Via
Benzinga
Topics
Artificial Intelligence
Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts
November 25, 2024
Editas Medicine faces a downgrade to Underperform from BofA, citing competition, limited catalysts, and a reduced price target of $1 from $13.
Via
Benzinga
Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference
November 12, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Breaking Down Beam Therapeutics: 5 Analysts Share Their Views
November 06, 2024
Via
Benzinga
Beam Therapeutics's Earnings: A Preview
November 04, 2024
Via
Benzinga
Deep Dive Into Beam Therapeutics Stock: Analyst Perspectives (6 Ratings)
September 11, 2024
Via
Benzinga
A Closer Look at 5 Analyst Recommendations For Beam Therapeutics
August 22, 2024
Via
Benzinga
This Clorox Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday
November 06, 2024
Via
Benzinga
Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial
November 05, 2024
Beam Therapeutics enrolls 35 patients in BEACON trial for BEAM-101 in sickle cell disease, with promising early safety and efficacy results, and progresses on Aalpha-1 Antitrypsin Deficiency
Via
Benzinga
Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting
November 05, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs
November 05, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting
October 29, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
September 26, 2024
Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths.
Via
Investor's Business Daily
Gene Editing Korro Bio's Preclinical Data 'Best-In-Class', Analyst Initiates With Outperform Rating
August 14, 2024
William Blair initiates coverage on Korro Bio highlighting its innovative RNA editing platform, ADAR-based OPERA. The analyst rates the stock Outperform, noting its potential in treating alpha-1...
Via
Benzinga
3 Gene Editing Stocks with Potential to Transform Medicine
August 09, 2024
Gene-editing holds substantial promise for treating thousands of diseases – creating incredible opportunities for gene editing stocks.
Via
InvestorPlace
BEAM Stock Earnings: Beam Therapeutics Beats EPS, Misses Revenue for Q2 2024
August 06, 2024
BEAM stock results show that Beam Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
Via
InvestorPlace
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results
August 06, 2024
From
Beam Therapeutics
Via
GlobeNewswire
ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio?
July 28, 2024
Top mid-cap stocks of the week: ASTS up 47.88%, GSHD up 39.86%, VSAT up 30.78%, VKTX up 29.86%, BEAM up 23.93%, CLDX up 19.72%
Via
Benzinga
IBM Posts Upbeat Earnings, Joins ServiceNow, Helmerich & Payne, RTX, Nasdaq And Other Big Stocks Moving Higher On Thursday
July 25, 2024
Via
Benzinga
Beam Therapeutics Stock Earns RS Rating Jump To 85
July 24, 2024
On Wednesday, Beam Therapeutics stock now clears the 80 or higher Relative Strength Rating threshold, with a jump from 65 to 85.
Via
Investor's Business Daily
Why Is Conn’s (CONN) Stock Down 36% Today?
July 24, 2024
Conn’s stock is falling on Wednesday as CONN investors react to reports of potential store closures and a bankruptcy filing.
Via
InvestorPlace
Topics
Bankruptcy
Trade of the Day: Buy Beam Therapeutics Call Options as BEAM Stock Heads to $40
July 24, 2024
Beam Therapeutics recently got a vote of confidence from a Wall Street analyst, providing fuel for further upside in BEAM stock.
Via
InvestorPlace
Danaher Posts Upbeat Earnings, Joins Spotify, MSCI, Owens & Minor And Other Big Stocks Moving Higher On Tuesday
July 23, 2024
Via
Benzinga
3 Gene Editing Stocks Shaping the Future of Medicine
July 22, 2024
Gene editing stocks offer a bold venture into biopharma's future, leveraging CRISPR technology for transformative healthcare solutions
Via
InvestorPlace
Cathie Wood-Led Ark Invest Sells $8M In Tesla Shares Despite Bullish Autonomy Forecast
July 18, 2024
Via
Benzinga
Beam Therapeutics Announces Transition of Chief Financial Officer
July 15, 2024
From
Beam Therapeutics
Via
GlobeNewswire
The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024
July 09, 2024
Finding undervalued gene editing stocks is easy, but having the patience to stick with them is the challenge.
Via
InvestorPlace
3 Stocks With the Potential to 10X Your Money
July 09, 2024
These three top high-growth potential stocks could offer substantial growth and give your portfolio a major boost.
Via
InvestorPlace
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
July 04, 2024
Biotech stocks are on the verge of a comeback after a period of underperformance amid a wave of FDA approvals.
Via
InvestorPlace
3 Stocks This Amazon-Backed AI Says Will Turn $1K into $1M by 2030
July 03, 2024
These high-risk, high-reward stocks have the potential to turn $1K into $1M by 2030, according to Amazon-backed AI Claude 3.5 Sonnet.
Via
InvestorPlace
Topics
Artificial Intelligence
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.